SALVO: Single Arm Trial of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma.

Lisa A Kottschade Gregory Russell Pond Anthony J Olszanski Yousef Zakharia Evidio Domingo-Musibay Ralph J Hauke Brendan D Curti Sarah Schober Mohammed M Milhem Matthew S Block Tina J Hieken Robert R McWilliams

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

Flip dose ipilimumab and nivolumab after resection of mucosal melanoma is associated with outcomes improved over that of surgical resection alone. Long term follow up, subgroup analyses and correlative studies are ongoing.

Keyphrases

phase iii
ulcerative colitis
skin cancer
early stage
clinical trial
study protocol
lymph node
phase ii
basal cell carcinoma
randomized controlled trial
open label
case control
type diabetes
prognostic factors
placebo controlled